AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 31 min read$FTH

Sensei Biotherapeutics GAAP EPS of -$0.79 misses by $0.01 (NASDAQ:FTH)

Sensei Biotherapeutics (FTH) reported Q3 GAAP EPS of -$0.79, missing estimates by $0.01. The company had $174.8M in cash and equivalents as of September 30, 2026, up from $21.2M at the end of 2025.

Original reporting
seekingalpha.com
Published Nov 3, 2026, 3:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$FTH
Bearish
medium confidence
Mentioned
$FTH
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$FTHBearishMed
01

Why it matters

The slight EPS miss may lead to short-term price decline, but the significant cash increase could support future R&D.

02

Market read

Earnings miss for a small-cap biotech, relevant for traders with exposure to the sector.

03

What to watch

The EPS miss is within a narrow range; market may have already priced in the result.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Sensei Biotherapeutics is a small-cap biotech focused on oncology therapeutics.

Company-level read

Ticker impact

$FTHBearishMedium confidence
Context

Sensei Biotherapeutics reported Q3 GAAP EPS of -$0.79, missing consensus by $0.01, with cash rising to $174.8M.

Expected impact

likely downward pressure as market prices in the EPS miss

Evidence & confidence

The EPS miss, albeit small, signals weaker profitability than expected, prompting traders to reassess valuation.

Market effects

Sector

Biotech sector may see modest pullback as earnings miss highlights execution risk.

Regional

Limited to U.S. small-cap biotech investors.

Global

Minimal global impact; primarily affects niche biotech investors.

Counterpoint

What could challenge this read

Cash buildup could fund upcoming trials, offering upside if milestones are met.

Key entities

  • company
    Sensei Biotherapeutics

    Biotech firm reporting Q3 results.

Read at source← All news

Related articles

NOV 3
$FTHMed

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates • Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end • FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected ad

SEC EDGAR 8-K2 min
NOV 3
$FTHMedAI 8/10

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates

Faeth Therapeutics (FTH) reported Q3 2026 results, highlighting FDA Fast Track designation for PIKTOR plus paclitaxel in advanced endometrial cancer. Topline Phase 2 trial results are expected by year-end. The company presented preclinical data on PIKTOR in breast cancer models. Cash reserves were $174.8M as of Q3 2026. R&D and G&A expenses increased, with a net loss of $20.4M for the quarter.

stocktitan.net2 min
OCT 23
$FTHMedAI 8/10

Faeth Therapeutics: Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

Faeth Therapeutics (FTH) presented preclinical data at ESMO 2026, showing PIKTOR inhibited tumor growth in breast cancer models, comparable or better than gedatolisib. PIKTOR, in combination with fulvestrant and palbociclib, achieved complete tumor growth inhibition. The company expects topline data from FTH-PIK-201 trial in endometrial cancer by year-end 2026 and interim data from FTH-PIK-101 trial in breast cancer in 2027.

finanznachrichten.de2 min
OCT 23
$FTHMedAI 8/10

Faeth presents preclinical data on PIKTOR in breast cancer

Faeth Therapeutics (FTH) presented preclinical data at the European Society for Medical Oncology Congress 2026, showing its drug PIKTOR inhibited tumor growth in breast cancer mouse models. PIKTOR, a combination of serabelisib and sapanisertib, achieved complete tumor growth inhibition or regression when combined with fulvestrant and palbociclib. The company is conducting Phase 2 trials in endometrial and breast cancer, with data expected by year-end 2026 and 2027, respectively.

investing.com2 min
OCT 7
$FTHMedAI 8/10

Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout

Sensei Biotherapeutics (FTH) presented data supporting its PIKTOR regimen, combining serabelisib and sapanisertib, ahead of an upcoming trial readout. The company reported improved progression-free survival in endometrial cancer patients and highlighted safety and dose-selection data. It also discussed potential market opportunities in breast and endometrial cancer, estimating a $5 billion and $1.5 billion annual market, respectively.

finance.yahoo.com2 min